CA2303945A1 - Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides - Google Patents

Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides Download PDF

Info

Publication number
CA2303945A1
CA2303945A1 CA002303945A CA2303945A CA2303945A1 CA 2303945 A1 CA2303945 A1 CA 2303945A1 CA 002303945 A CA002303945 A CA 002303945A CA 2303945 A CA2303945 A CA 2303945A CA 2303945 A1 CA2303945 A1 CA 2303945A1
Authority
CA
Canada
Prior art keywords
pcr
mrd
probe
detection
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303945A
Other languages
English (en)
Inventor
Jacobus Johannes Maria Van Dongen
Martha Jacoba Pongers-Willemse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus Universiteit Rotterdam
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303945A1 publication Critical patent/CA2303945A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention porte sur le diagnostic du cancer, et plus spécifiquement sur le contrôle du développement pathologique pendant et après traitement. Cette invention porte donc sur un procédé de détermination d'une pathologie résiduelle minime, ce procédé consistant à amplifier les molécules d'acide nucléique à l'aide d'au moins une amorce réagissant avec un segment génique commun, et à identifier des séquences d'acide nucléique spécifiques de la tumeur maligne en effectuant une hybridation avec une sonde fluorogène réagissant spécifiquement et sélectivement avec des séquences d'acide nucléique spécifiques de la tumeur maligne.
CA002303945A 1997-09-18 1998-09-18 Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides Abandoned CA2303945A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97202858 1997-09-18
EP97202858.3 1997-09-18
PCT/NL1998/000542 WO1999014366A2 (fr) 1997-09-18 1998-09-18 Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides

Publications (1)

Publication Number Publication Date
CA2303945A1 true CA2303945A1 (fr) 1999-03-25

Family

ID=8228734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303945A Abandoned CA2303945A1 (fr) 1997-09-18 1998-09-18 Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides

Country Status (4)

Country Link
EP (1) EP1015635A2 (fr)
AU (1) AU9190098A (fr)
CA (1) CA2303945A1 (fr)
WO (1) WO1999014366A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3802870A4 (fr) * 2018-06-11 2022-03-23 Monoquant PTY LTD Procédé d'amplification et amorces pour leur utilisation à l'intérieur du procédé

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7762091A (en) * 1990-03-30 1991-10-30 City Of Hope Detection of minimal residual disease in lymphoid malignancies
AU9147991A (en) * 1990-11-28 1992-06-25 University Of Texas System, The Methods and compositions for detecting and quantitating hematopoietic tumors
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
DE69610304T2 (de) * 1995-05-05 2001-04-05 Perkin Elmer Corp Methoden and reagentien fuer die kombination einer pcr-amplifizierung mit einem hybridisierungs-assay
BR9609912A (pt) * 1995-07-27 1999-12-21 Dalgety Plc Processo e kit para determinar o genotipo de cor da pelagem de um suìno

Also Published As

Publication number Publication date
WO1999014366A3 (fr) 1999-05-06
AU9190098A (en) 1999-04-05
EP1015635A2 (fr) 2000-07-05
WO1999014366A2 (fr) 1999-03-25

Similar Documents

Publication Publication Date Title
Pongers-Willemse et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes
Pallisgaard et al. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t (12; 21) TEL‐AML1 fusion transcript
Verhagen et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia
Lawler et al. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction
Yokota et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients
Dippel et al. Clonal T‐cell receptor γ‐chain gene rearrangement by PCR‐based GeneScan analysis in advanced cutaneous T‐cell lymphoma: a critical evaluation
Downing et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8; 21)(q22; q22) translocation
Szczepariski et al. Minimal residual disease in leukaemia patients
Deane et al. Immunoglobulin gene ‘fingerprinting’: an approach to analysis of B lymphoid clonality in lymphoproliferative disorders
Peterson et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli
Ugozzoli et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation
Miyauchi et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia
Zwicky et al. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation
EP2504451B1 (fr) Procédés destinés à prédire l'issue clinique d'un cancer
US20080108509A1 (en) Process for Recognizing Signatures in Complex Gene Expression Profiles
Dölken et al. Quantitative detection of t (14; 18)-positive cells by real-time quantitative PCR using fluorogenic probes
US20090253583A1 (en) Hematological Cancer Profiling System
US20200017915A1 (en) Methods and compositions for determining responsiveness to antibody therapy
US5024934A (en) Detection of minimal numbers of neoplastic cells carrying DNA translocations by DNA sequence amplification
Tyler et al. Personalized chimerism test that uses selection of short tandem repeat or quantitative PCR depending on patient's chimerism status
Jorgensen et al. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications
Hosler et al. Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma
Luthra et al. Real-time 5′→ 3′ exonuclease-based PCR assay for detection of the t (11; 14)(q13; q32)
Saffroy et al. Real‐time quantitation of bcr‐abl transcripts in haematological malignancies
Yin Minimal residual disease in acute myeloid leukaemia

Legal Events

Date Code Title Description
FZDE Dead